According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 1/9

ΕN

Publication: 22/08/2024 Revision: XX/XX/XXXX

Version: 00



## **ORLISTATUM**

## SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1 Product identifier

Product name: Orlistat

Orlistatum Orlistat Orlistat Orlistat

N° CAS: 96829-58-2 N° EC: 639-755-1

## 1.2 Relevant identified uses of the substance/mixture and uses advised against

Identified uses: Active Pharmaceutical Ingredient or Excipient.

## 1.3 Details of the supplier of the safety data sheet

Company: Magis-Pharma NV

Neerlandweg 24 2610 Wilrijk Belgium

Telephone: (+32) (0)3 457 11 76
Email: info@magis-pharma.be
Web page: www.magis-pharma.be

## 1.4 Emergency telephone number

Public utility foundation: Belgisch Antigifcentrum Centre Antipoisons Belge

Telephone: (+32) (0)70 245 245 (Service 24/7)

Web page: www.antigifcentrum.be www.centreantipoisons.be

#### **SECTION 2: HAZARDS IDENTIFICATION**

## 2.1 Classification of the substance/mixture

## Classification according to (EC) n° 1272/2008

Aquatic Chronic (category 3) H412

#### 2.2 Label elements

## Labelling according to (EC) n° 1272/2008

Hazard pictogram(s): Not applicable.
Signal word(s): Not applicable.

Hazard statements:

H412 Harmful to aquatic life with long lasting effects.

Precautionary statements: Not applicable.

Additional applicable label Not applicable.

elements:

#### 2.3 Other hazards

Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 2/9

ΕN

Publication: 22/08/2024 Revision: XX/XX/XXXX

Version: 00



## **ORLISTATUM**

## **SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS**

#### 3.1 Substances

Product name: Orlistat

IUPAC name: [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-

methylpentanoate

Synonyms: Tetrahydrolipstatin

L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-

 $[2\alpha(R^*), 3\beta]]$ -

N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]-2-

oxetanone

 N° CAS:
 96829-58-2

 N° EC:
 639-755-1

 Molecular Formula:
 C29H53NO5

Content: Orlistat contains NLT 98.0% and NMT 101.5% of orlistat (C<sub>29</sub>H<sub>53</sub>NO<sub>5</sub>), calculated on

the anhydrous, solvent-free basis.

### 3.2 Mixtures

Not applicable.

### **SECTION 4: FIRST AID MEASURES**

## 4.1 Description of first aid measures

General notes: Consult a physician. Show this safety data sheet to the doctor in attendance.

After inhalation: If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Consult a physician.

After skin contact: Wash off with soap and plenty of water. Consult a physician.

After eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

After ingestion: Never give anything by mouth to an unconscious person. Rinse mouth with water.

Consult a physician.

Self-protection of the first

aider: Not applicable.

## 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11.

## 4.3 Indication of any immediate medical attention and special treatment needed

Not available.

## **SECTION 5: FIREFIGHTING MEASURES**

#### 5.1 Extinguishing media

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon

dioxide.

Unsuitable extinguishing media: Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00) Page 3/9

22/08/2024

ΕN

Publication: Revision: XX/XX/XXXX

00 Version:



**ORLISTATUM** 

## 5.2 Special hazards arising from the substance/mixture

Carbon dioxide, nitrogen oxides (NO<sub>x</sub>), hydrogen chloride gas.

## 5.3 Advice for firefighters

Surrounding fires: Not available.

Protection against fire: Wear self-contained breathing apparatus for fire fighting if necessary.

Hazardous combustion products: Not available.

## **SECTION 6: ACCIDENTAL RELEASE MEASURES**

### 6.1 Personal precautions, protective equipment and emergency procedures

#### For non-emergency personnel

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

## For emergency responders

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

## **6.2 Environmental precautions**

Do not let product enter drains.

## 6.3 Methods and material for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

### **6.4 Reference to other sections**

For disposal see section 13.

## **SECTION 7: HANDLING AND STORAGE**

### 7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and Precautions for safe handling:

aerosols. For precautions see section 2.2.

Personal protection: Not available.

Technical protective measures: Provide appropriate exhaust ventilation at places where dust is

formed.

Handling: Not available.

### 7.2 Conditions for safe storage, including any incompatibilities

In a well-closed container. Storage:

Conditions for safe storage, including any Store in cool place. Keep container tightly closed in a dry and well-

incompatibilities: ventilated place. Store under inert gas. Hygroscopic. Store at a

temperature of 2°C to 8°C.

Not available. Storage – away from:

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00) Page 4/9

Publication: 22/08/2024

XX/XX/XXXX

ΕN

Version: 00

Revision:



## **ORLISTATUM**

## 7.3 Specific end use(s)

Active Pharmaceutical Ingredient or Excipient

## **SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

#### 8.1 Control parameters

Not available.

### **8.2 Exposure controls**

## Appropriate engineering control

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

## **Individual protection measures**

Eye/face protection: Safety glasses with side-shields conforming to EN166. Use equipment for eye

protection tested and approved under appropriate government standards such as

NIOSH (US) or EN 166(EU).

Skin protection: Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal

technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws

and good laboratory practices. Wash and dry hands.

The selected protective gloves have to satisfy the specifications of EU Directive

89/686/EEC and the standard EN 374 derived from it.

Impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hand protection: Not determined.

Respiratory protection: For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.

For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143)

respirator cartridges.

Use respirators and components tested and approved under appropriate government

standards such as NIOSH (US) or CEN (EU).

Thermal hazards: Not determined.

## **Environmental exposure control**

Do not let product enter drains.

## **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

## 9.1 Information on basic physical and chemical properties

Appearance: Not available.

Odour: Not available.

Odour threshold: Not available.

pH: Not available.

Melting/freezing point: Not available.

Initial boiling point: Not available.

Boiling range: Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00) Page 5/9

ΕN

Publication: 22/08/2024 Revision: XX/XX/XXXX

Version: 00



## **ORLISTATUM**

Not available. Flash point: Evaporation rate: Not available.

Flammability (solid/gas): Not available.

Upper/lower flammability or

explosive limits:

Not available.

Vapour pressure: Not available. Vapour density: Not available. Relative density: Not available. Solubility: Not available. Not available. Solubility in water: Partition coefficient Not available.

(n-octanol/water):

Not available. Auto-ignition temperature: Decomposition temperature: Not available. Viscosity: Not available. Not available. Explosive properties: Oxidising properties: Not available.

## 9.2 Other information

Not available.

## **SECTION 10: STABILITY AND REACTIVITY**

## 10.1 Reactivity

Not available.

## 10.2 Chemical stability

Stable under recommended storage conditions.

## 10.3 Possibility of hazardous reactions

Not available.

## 10.4 Conditions to avoid

Avoid moisture.

## 10.5 Incompatible materials

Acids, acid chlorides, acid anhydrides, oxidizing agents.

## 10.6 Hazardous decomposition products

Other decomposition products: Not available.

In the event of fire: see section 5.

#### **SECTION 11: TOXICOLOGICAL INFORMATION**

## 11.1 Information on toxicological effects

Not available. Acute toxicity: Skin corrosion/irritation: Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00) Page 6/9

22/08/2024

ΕN

Revision: XX/XX/XXXX

Version: 00

Publication:



## **ORLISTATUM**

Serious eye damage/irritation: Not available.

Respiratory/skin sensitisation: Prolonged or repeated exposure may cause allergic reactions in certain sensitive

individuals. The preceding data, or interpretation of data, was determined using

Quantitative Structure Activity Relationship (QSAR) modeling.

Germ cell mutagenicity: Not available.

Carcinogenicity: IARC: No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

Reproductive toxicity: Not available.

Summary of evaluation of the Not available.

CMR properties:

STOT-single exposure: Inhalation - May cause respiratory irritation.

STOT-repeated exposure: Not available.
Aspiration Hazard: Not available.

Other: To the best of our knowledge, the chemical, physical, and toxicological properties

have not been thoroughly investigated.

## 11.2 Additional information on potential adverse human health effects and symptoms

Eye contact:

Skin contact:

Not available.

Inhalation:

Not available.

Ingestion:

Not available.

Not available.

Not available.

#### **SECTION 12: ECOLOGICAL INFORMATION**

## 12.1 Toxicity

Not available.

## 12.2 Persistence and degradability

Not available.

## 12.3 Bioaccumulative potential

Not available.

## 12.4 Mobility in soil

Not available.

### 12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted.

## 12.6 Other adverse effects

Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 7/9 22/08/2024 XX/XX/XXXX

ΕN

Version: 00

Publication:

Revision:

M A G I S PHARMA

## **ORLISTATUM**

## **SECTION 13: DISPOSAL CONSIDERATIONS**

#### 13.1 Waste treatment methods

#### **Product**

Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this material is highly flammable. Offer surplus and nonrecyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.

## **Contaminated packaging**

Dispose of as unused product.

## **SECTION 14: TRANSPORT INFORMATION**

### Transport information according to ADR/RID/IMDG/ICAO/IATA

### 14.1 UN Number

ADR/ RID(Land), IMDG(Sea),

Not classified.

IATA/ICAO (Air):

## 14.2 UN proper shipping name

ADR/ RID(Land), IMDG(Sea),

Not classified.

IATA/ICAO (Air):

## 14.3 Transport hazard class(es)

ADR/RID(Land),IMDG(Sea),

Not classified.

IATA/ICAO (Air):

### 14.4 Packing group

ADR/RID(Land),IMDG(Sea),

Not classified.

IATA/ICAO (Air):

### 14.5 Environmental hazards

ADR/RID(Land),IMDG(Sea),

Not classified.

IATA/ICAO (Air):

## 14.6 Special precautions for user

Not available.

## 14.7 Transport in bulk according to annex II of Marpol and the IBC Code

Not available.

## 14.8 Additional transport information

Not available.

### **SECTION 15: REGULATORY INFORMATION**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance/mixture

Hazard symbol: Not applicable.
Risk phrases: Not applicable.
Safety phrases: Not applicable.

## 15.2 Chemical safety assessment

For this product a chemical safety assessment was not carried out.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00) Page 8/9

Publication: 22/08/2024

XX/XX/XXXX

ΕN

Version: 00

Revision:



## **ORLISTATUM**

### **SECTION 16: OTHER INFORMATION**

### 16.1 Changes since the previous version

Not applicable.

## 16.2 Abbreviations and acronyms used

ADR: European Agreement concerning the International Carriage of Dangerous Goods by

Road

CAS: Chemical Abstracts Service (division of the American Chemical Society)

EC (number): European Community (number)

IATA: International Air Transport Association
ICAO: International Civil Aviation Organization

IMDG: International Maritime Code for Dangerous GoodsIUPAC: International Union of Pure and Applied ChemistryPBT: Persistent, Bioaccumulative and Toxic substance

RID: Regulations Concerning the International Transport of Dangerous Goods by Rail

STOT: Specific Target Organ Toxicity
UN (number): United Nations (number)

vPvB: very Persistent and very Bioaccumalative

## 16.3 Key literature references/sources for data

European Chemicals Agency.

https://www.echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database/

## 16.4 Method of classification in case of mixture

Not applicable.

## 16.5 Relevant Hazard statements and/or precautionary statements

For information on hazard and/or precautionary statements refer to section 2 up to and including section 15.

#### 16.6 Training advisement

Not available

## 16.7 Notice for user(s)

The information provided in this MSDS has been established in accordance with Commission Regulation (EU) 2015/830 of 28 May 2015, amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council, on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94, as well as Council Directive 76/769/EEC and Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC of the Commission.

This MSDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. The information has been compiled from sources considered to be dependable and is accurate to the best of the FSA NV's knowledge. However, the information is provided without any representation or warranty, expressed or implied regarding its accuracy or correctness. FSA NV cannot assume responsibility for adverse events which may occur in the use and/or misuse of this product and expressly disclaims liability for loss, damage and/or expense arising out of or in any way connected with the handling, storage, use and/or disposal of this product.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

**ORLISTATUM** 

EN

FORM-06-14-01 (V00)

Page 9/9 Publication: 22/08/2024

Revision: XX/XX/XXXX

Version: 00



## 16.8 Department issuing MSDS

Quality Department FAC SECUNDUM ARTEM NV info@magis-pharma.be